Hepion Pharmaceuticals‘ CRV431 has a similar, or even greater effect in reducing markers of idiopathic pulmonary fibrosis (IPF) in lung tissue, compared with standard-of-care IPF treatment, the company reported. The therapy had positive results in lung tissue from an IPF patient, according to Hepion. CRV431 is a…
CRV431 Reduced Fibrosis Markers in IPF Lung Tissue, Hepion Reports
This weekend, we will celebrate my mom’s re-birthday. It is hard to believe that an entire year has passed since my mom, Holly, had a double-lung transplant. The important moments of that day remain vivid in my memory. The phone rang at about 8 a.m. My…
The U.S. Food and Drug Administration (FDA) and Bellerophon Therapeutics agreed on the design of Bellerophon’s Phase 3 trial to test INOpulse — inhaled nitric oxide — in people with pulmonary fibrosis (PF) who are at risk for pulmonary hypertension (PH), the company said. INOpulse is a device that…
This week, March 8-14, is National Pulmonary Rehab Week. As a pulmonary fibrosis and single-lung transplant patient, I vow to promote pulmonary rehab awareness on behalf of my fellow Pulmonary Fibrosis News Forum members and others who are suffering from a debilitating lung disease. I am currently participating in…
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still lacking treatment. And federal incentives to boost treatment development for these rare diseases have primarily focused not on creating new…
I am writing this from seat 17A on a flight home from California. I see nothing but fluffy white clouds and sunshine from up here, and I can’t help but wipe a tear from my eye. I have completed another incredible trip despite living with idiopathic pulmonary fibrosis (IPF). When…
The FPR-1 protein is necessary for the recruitment of immune cells, namely neutrophils and inflammatory macrophages, to the lungs where they promote pulmonary fibrosis (PF), a mouse study shows. Depletion of FPR-1 or neutrophils prevented lung fibrosis and inflammation, supporting their potential as therapeutic targets in PF. The study…
Since being diagnosed with idiopathic pulmonary fibrosis (IPF) nearly four years ago, I’ve learned a lot about chronic illness communities. Additionally, I’ve learned about the many professional roles that affect patients, families, and caregivers living with chronic illnesses. All of these roles are important in helping those of us…
The Pulmonary Fibrosis Foundation (PFF) and Celgene, a subsidiary of Bristol-Myers Squibb, are leading a collaboration with the long-term goal of streamlining the development of targeted treatment strategies for idiopathic pulmonary fibrosis (IPF), and the identification of disease biomarkers. In the majority of cases, the cause…
Pliant Therapeutics has raised $100 million in Series C financing that will support the clinical development of PLN-74809, a candidate therapy for idiopathic pulmonary fibrosis (IPF)Â and primary sclerosing cholangitis (PSC), a liver disease characterized by progressive inflammation and fibrosis of the bile ducts. The funding will…
